first_img News Follow the news on Syria SyriaMiddle East – North Africa Condemning abuses January 4, 2016 Find out more Organisation Young Syrian press photographer killed in Aleppo June 29, 2016 Constant threats against journalists in Syria April 29, 2016 Find out more © Zamanalwsl Receive email alerts Reporters Without Borders (RSF) is saddened by the news of Syrian citizen-cameraman Khaled El Issa’s death in a Turkish hospital from injuries sustained in a bomb attack in the northwestern city of Aleppo. RSF also condemns Islamic State’s filmed murders of five Syrian citizen-journalists in the eastern city of Deir Ezzor. to go furthercenter_img RSF_en News Issa, 25, died in a hospital in the Turkish city of Antakya on the evening of 24 June from injuries caused late on the night of 16 June by a homemade bomb targeting the building where he lived in the Aleppo district of Chaar with fellow journalist Hadi AbdullahHadi Abdullah.Abdullah was also badly injured in the bombing, which was widely condemned on social networks as an attempt to murder the two Syrian journalists and activists. Two days before the bombing, both Issa and Abdullah sustained head injuries while covering the fighting in Aleppo.The gruesome murders in Deir Ezzor of five citizen-journalists accused of criticizing Islamic State in their reporting or just working for news media were shown in a video entitled “Inspiration of Satan” that the extremist group released on 26 June.“We offer our heartfelt condolences to the families of the victims and firmly condemn all threats and attacks against journalists, both professional and non-professional, by the various parties to the conflict in Syria,” said Alexandra El Khazen, the head of RSF’s Middle East desk.“These journalists take enormous risks just to do their work. Not only are all parties to the conflict responsible for abuses against journalists but it is also crucial for the authorities in receiving countries to protect journalists fleeing from the war’s horrors.”Both Issa and Abdullah were hospitalized in Turkey. Whereas Abdullah’s condition stabilized, Issa remained in a coma and in a critical condition. On 23 June, a campaign was launched on social networks in support of Issa and to pressure the German government to give him a medical visa. The visa was finally issued but Issa succumbed to his injuries before he could be transferred.The Islamic State video showed the five citizen-journalists talking about their journalistic activities and then being murdered in various brutal ways. The video made directs threats against all those who work for media outlets or NGOs that criticize Islamic State, both within Syria and abroad.Islamic State also claimed responsibility for Syrian journalist Zaher Al Sherqat’s murder in the Turkish city of Gaziantep in April and showed the photos of Naji Jerf, Ibrahim Abdel Qader and Fares Hammadi – other Syrian journalists and citizen-journalists murdered in Turkey. RSF has not been able to verify the journalistic activity of the citizen-journalists shown in the video.Last year, RSF asked the UN Security Council to refer crimes against journalists in Iraq and Syria to the International Criminal Court.Syria is ranked 177th out of 180 countries in RSF’s 2016 World Press Freedom Index. SyriaMiddle East – North Africa Condemning abuses News Help by sharing this information Syria : RSF condemns attack by gunmen on Syrian community radio station and its executive director June 10, 2016 Find out more News One year on from Charlie, RSF publishes “Jihad against journalists”last_img read more

first_img WhatsApp Pinterest Facebook Twitter Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results Pinterest By Digital AIM Web Support – February 23, 2021 WhatsAppcenter_img Facebook SAN DIEGO, Feb. 23, 2021 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its recent corporate activities and outlook. “The fourth quarter capped an extraordinary year for Halozyme during which we transitioned to a profitable, high-growth company with strong prospects for continued growth over the long-term,” said Dr. Helen Torley, president and chief executive officer. “Our strong growth prospects are fueled by recent product approvals for subcutaneous DARZALEX® (daratumumab) and Phesgo® (pertuzumab, trastuzumab and hyaluronidase) utilizing our ENHANZE® technology. Building on our portfolio of 5 commercialized partner products, we project the expansion of our development pipeline, including 4 products being evaluated in 7 phase 3 studies utilizing our ENHANZE® technology. We believe this advancing pipeline of products utilizing our ENHANZE® technology is setting the potential for multiple waves of future product launches that will deliver long-term growth in revenues, profitability and cash flow.” Fourth Quarter 2020 and Recent Highlights Include: In February 2021, argenx announced a “go” decision for its ADHERE trial evaluating subcutaneous (SC) efgartigimod with ENHANZE® technology in chronic inflammatory demyelinating polyneuropathy (CIDP). argenx plans to continue enrollment to include approximately 130 patients to support potential registration of SC efgartigimod for the treatment of CIDP.In January 2021, ENHANZE® partner Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) accelerated approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. AL amyloidosis is a rare and potentially fatal disease that develops when plasma cells in the bone marrow generate abnormal light chains, which form amyloid deposits in vital organs and lead to organ deterioration. There were previously no approved therapies for the disease.In January 2021, argenx initiated a Phase 3 study of ARGX-113 with ENHANZE® technology in pemphigus vulgaris and pemphigus foliaceus, rare autoimmune diseases that cause painful blisters on the skin and mucous membranes.In December 2020, argenx initiated a Phase 3 study of ARGX-113 with ENHANZE® technology for patients with immune thrombocytopenia (ITP), an immune disorder in which the blood does not clot normally, resulting in a $15 million payment to Halozyme.In December 2020, Roche initiated a Phase 3 study in patients with non-small cell lung cancer for Tecentriq® (atezolizumab) with ENHANZE® technology, resulting in a $17 million payment to Halozyme.In December 2020, the Company announced that the European Commission approved Roche’s Phesgo®, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with ENHANZE® technology, administered by SC injection for the treatment of patients with early and metastatic HER2-positive breast cancer. This was the first time the European Commission approved a product combining two monoclonal antibodies that can be administered by a single SC injection utilizing ENHANZE® technology.In November 2020, the Company announced a global collaboration and license agreement that provides Horizon Therapeutics plc exclusive access to ENHANZE® technology for SC formulation of medicines targeting IGF-1R for which the Company received an upfront payment of $30 million. Horizon intends to use ENHANZE® technology to develop a SC formulation of TEPEZZA® (teprotumumab-trbw), indicated for the treatment of Thyroid Eye Disease, a serious, progressive and vision-threatening rare autoimmune disease, potentially shortening drug administration time, reducing healthcare practitioner time and offering additional flexibility and convenience for patients.In November 2020, Janssen initiated a Phase 1 study of amivantamab utilizing ENHANZE® technology in advanced solid tumors.In November 2020, the Company announced that Janssen submitted regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of DARZALEX FASPRO® in the U.S. and as DARZALEX® SC in the European Union (EU) utilizing ENHANZE® technology in combination with pomalidomide and dexamethasone (D-Pd) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.In November 2020, Janssen submitted a Type II variation application to the EMA seeking European approval for DARZALEX® SC utilizing ENHANZE® technology to be used in the treatment of patients with AL amyloidosis.In October 2020, the Company announced that argenx expanded its existing global collaboration and license agreement that was signed in February 2019. Under the expansion, argenx gained the ability to exclusively access Halozyme’s ENHANZE® drug delivery technology for three additional targets upon nomination for a total of up to six targets. To date, argenx has nominated two targets including the human neonatal Fc receptor FcRn, which is blocked by efgartigimod, and complement component C2.During the fourth quarter, the Company repurchased approximately 1.1 million shares of common stock for $37.6 million at an average price per share of $34.36, bringing the total 2020 repurchases to $150.0 million at an average price of $23.05. Fourth Quarter and Full Year 2020 Financial Highlights Revenue for the fourth quarter was $121.7 million compared to $53.7 million for the fourth quarter of 2019. The year-over-year increase was primarily driven by a $30.0 million upfront payment from Horizon, a $15.0 million sales milestone from Janssen, an increase in royalty revenue following the strong DARZALEX FASPRO® launch during the second quarter and an increase in product sales. Revenue for the quarter included $32.0 million in royalties, an increase of 86% compared to $17.2 million in the prior year period. Total revenues for the full year were $267.6 million, compared with $196.0 million in 2019, representing growth of 37% year over year.Research and development expenses for the fourth quarter were $7.4 million, compared to $45.1 million for the fourth quarter of 2019. The decrease in expenses was due to a decrease in clinical trial activities-related costs as a result of the Company halting its oncology drug development efforts beginning in November 2019 and one-time restructuring charges of $17.2 million in the prior year related to the shift in strategic focus to the Company’s ENHANZE® technology. Research and development expenses for the full year were $34.2 million, compared with $140.8 million in 2019.Selling, general and administrative expenses for the fourth quarter were $10.4 million, compared to $23.9 million for the fourth quarter of 2019. The decrease was due to lower compensation and commercial-related expenses related to the corporate restructuring announced in November 2019 and a one-time restructuring charge of $11.2 million in the prior year. Selling, general and administrative expenses for the full year were $45.7 million, compared with $77.3 million in 2019.Operating income for the fourth quarter was $77.6 million, compared to an operating loss of $32.1 million in the fourth quarter of 2019. Operating income for the full year was $144.3 million, compared to an operating loss of $67.6 million in 2019.Net income for the fourth quarter was $73.2 million, or $0.50 per share, compared to a net loss in the fourth quarter of 2019 of $34.4 million, or loss of $0.24 per share. Net income for the full year was $129.1 million or $0.91 per share, compared to a net loss of $72.2 million or loss of $0.50 per share in 2019.Cash, cash equivalents and marketable securities were $368.0 million at December 31, 2020, compared to $421.3 million at December 31, 2019.During 2020, the Company repurchased 6.5 million shares of common stock for $150 million at an average price of $23.05, bringing the total for share repurchases since the announcement of the Company’s three-year share repurchase program to $350.0 million at an average price of $19.88. Financial Outlook for 2021 Based on the latest information from collaboration partners and planned expenditures for the year, the Company expects: Revenues of $375 million to $395 million, representing year-over-year growth of 40%-48%, with revenues from royalties projected to approximately double versus 2020;Operating Income of $215 million to $235 million, representing year-over-year growth of 49%-63%;Earnings per share on a GAAP basis of $1.40 to $1.55, representing year-over-year growth of 54%-70%. The Company plans to repurchase up to $125 million in common stock during 2021 as part of the $550 million three-year share repurchase plan authorized by Halozyme’s board of directors in 2019. The amount and timing of shares to be repurchased in 2021 will be subject to a variety of factors including market conditions, other business considerations and applicable legal requirements. Webcast and Conference Call Halozyme will webcast its Quarterly Update Conference Call for the fourth quarter of 2020 today, Tuesday, February 23, 2021 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Torley will lead the call, which will be webcast live through the “Investors” section of Halozyme’s corporate website and a replay will be available following the close of the call. To register for this conference call, please use this link: http://www.directeventreg.com/registration/event/7096809. After registering, you will receive an email confirmation that includes dial in details and unique conference call codes for entry. Registration is open through the live call. However, to ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. About Halozyme Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients’ lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme’s commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme’s proprietary enzyme rHuPH20 forms the basis of the ENHANZE® technology and is used to facilitate the delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion, argenx and Horizon Therapeutics. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company’s partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com. Safe Harbor Statement In addition to historical information, the statements set forth in this press release include forward-looking statements including, without limitation, statements concerning the Company’s expected future financial performance (including the Company’s financial outlook for 2021) and expectations for future growth, profitability, revenue, operating income, cash flow, expenses and earnings-per-share and the Company’s plans to continue its share repurchase program. Forward-looking statements regarding the Company’s ENHANZE® drug delivery technology may include the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs and facilitating more rapid delivery of injectable medications through subcutaneous delivery. Forward-looking statements regarding the Company’s ENHANZE® business may include potential growth driven by our partners’ development and commercialization efforts, the size and growth prospects of our partners’ drug franchises, potential new ENHANZE® collaborations and collaborative targets and regulatory review and potential approvals of new ENHANZE® products. These forward-looking statements are typically, but not always, identified through use of the words “believe,” “enable,” “may,” “will,” “could,” “intends,” “estimate,” “anticipate,” “plan,” “predict,” “probable,” “potential,” “possible,” “should,” “continue,” and other words of similar meaning and involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Actual results could differ materially from the expectations contained in these forward-looking statements as a result of several factors, including unexpected levels of revenues, expenditures and costs, inability to sustain profitability, unexpected delays in the execution of the Company’s share repurchase program, unexpected results or delays in the growth of the Company’s ENHANZE® business, or in the development, regulatory review or commercialization of ENHANZE® products, including any potential delays caused by the current COVID-19 global pandemic, regulatory approval requirements, unexpected adverse events or patient outcomes and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company’s most recently filed Annual Report on Form 10-K filed with the Securities and Exchange Commission. Contact: Al Kildani Vice President, Investor Relations and Corporate Communications 858-704-8122 [email protected] View original content to download multimedia: http://www.prnewswire.com/news-releases/halozyme-reports-fourth-quarter-2020-results-and-full-year-2020-results-301233889.html SOURCE Halozyme Therapeutics, Inc. Previous articleIndian Country gripped by Haaland hearing for top US postNext articleSquare, Inc. Announces Fourth Quarter and Full Year 2020 Results Digital AIM Web Support TAGS  Twitter Local NewsBusinesslast_img read more

first_imgWith a Facebook page, a photo and video campaign and a petition in the works, several graduate students in peace studies are trying to raise awareness about a recent outbreak of mob violence against immigrants in South Africa.The attacks, in which people have been shot and stabbed and shops looted and burned, have left several dead and thousands of migrants displaced, The Guardian reported. Most of the victims are from nearby African countries such as Mozambique, Malawi and Zimbabwe. In the face of international backlash, South Africa arrested hundreds and sent its army to parts of the cities of Johannesburg and Durban, where the violence is centered, to quell the unrest.The violence is the latest in a series of outbreaks over the past several years. Sarah Bosha, a second-year masters student in peace studies who helped form the Notre Dame campaign, said some South Africans, especially in poorer areas, believe foreigners take away South Africans’ jobs.Francis Opio, also a second-year masters student, said he and other students from Africa had the idea for the project, which is unaffiliated with other campus organizations, last week after they talked with each other about what they had heard about the violence.“We thought, not only as peace studies students but also as human beings, we needed to speak up,” Opio said. “How could this be happening to an African but also being orchestrated by an African? It was really horrible.”The campaign, called “Students Against Violence,” began Friday outside the library, where students encouraged passersby to record a video message or take a photo with a sign that said “Say No to Xenophobia.” The students created a Facebook page to post the photos and discuss news from Africa.The group will also collect signatures for a petition, which they will submit to the South African consulate in Chicago, Bosha said. Bosha, who is from Zimbabwe, said the petition stems from her and other students’ dismay at the slow response of international leaders.“We felt like there’s a deafening silence from other African governments — I know my leader, President [Robert] Mugabe, didn’t say anything for a long time,” she said. “The South African president didn’t quite say anything for a long time, the AU took a really long time to say something, and it was disheartening to us because there were people from our country, people from other countries that were being killed, and it just seemed like it was business as usual. No one seemed moved, who had the authority to do something about it.”The petition will remind the South African government about its obligation to uphold the right to life under the African Charter on Human and People’s Rights, Bosha said.“The idea is to call upon the South African government to what it’s supposed to do according to its treaty obligations and also to call upon South Africans themselves that are committing the violence — it’s not all of them, but the ones that are — that this is against the values that we as a continent uphold,” Bosha said.Bosha said the campaign will also address a general lack of knowledge about the situation in South Africa.“It was interesting to see how something so huge as someone’s loss of life in such a terrible way like being burned to death or being decapitated or being murdered could slip by the eyes of the world,” she said. “It surprised me that some people didn’t know — but it’s not something that was blasted in international media.”First-year masters student Christian Cirhigiri said after the petition is submitted, the campaign will go beyond the immediate problem of violence in South Africa. He said the social media platform will be a space both to raise public awareness of African news and for African students to talk about issues on the continent, such as attacks by Nigerian terror group Boko Haram or the killing of 30 Ethiopian Christians by ISIS.“This is not just for South Africa,” he said. “We would like to create a space for a movement here on campus where African issues are brought to light, that the Notre Dame community gets to know or gets to feel that we are representing nations that are affected, and we would like to have their support as well as the support of leaders here.”Tags: africa, Peace Studies, south africa, students against violence, violence, xenophobialast_img read more

first_imgPhotos: Matthew Murphy | Styling: David Withrow | Hair & Makeup: Alex Michaels | Production Assistant: Evan Zimmerman | Shot at Studios LIC The infectious Sergio Trujillo nabbed a 2016 Tony nomination for On Your Feet!’s vibrant choreography. Beginning on Broadway as a dancer in Guys and Dolls and Fosse, the Toronto native had his sights set on (literally) making moves, going on to choreograph Main Stem smashes like Memphis, Jersey Boys, The Addams Family and Next to Normal (all of which ran simultaneously in 2011, btw). On Your Feet! marks his first Tony nod, and by the looks of the killer ensemble, which includes Carlos E. Gonzalez, Tanairi Sade Vasquez, Nina Lafarga and Luis Salgado, this is only the beginning. Photographer Matthew Murphy captured them where they shine brightest—on their feet! Check out the colorful shoot!VIEW THE PHOTO GALLERY Related Shows Carlos E. Gonzalez, Tanairi Sade Vasquez, Sergio Trujillo, Nina Lafarga & Luis Salgado(Photo: Matthew Murphy) Show Closed This production ended its run on Aug. 20, 2017 On Your Feet! View Commentslast_img read more

first_imgAccording to Brightline spokesman Mike Hicks, the vehicle went around the gates that were already lowered as the train was approaching and was struck by the train.Pompano Beach Fire Rescue officials said the vehicle caught fire after the crash.Passengers were off-loaded from the train and directed to a nearby bus.There were no reports of any injured passengers on the train. BSO homicide investigators are looking into the death of a person who was killed Tuesday morning in a fiery crash involving a Brightline train in Pompano Beach.The crash was reported in the area of Atlantic Boulevard and North Dixie Highway.last_img

first_imgWhile I don’t like to get hung up on numbers, it does help people learn to make more conscious food decisions when they can actually see tangible evidence that the “granola” bar they ate contained mostly fat (and sugar!), and in fact was just a glorified chocolate bar.This little formula below can help you figure out if what you’re about to stuff in your mouth is actually that good for you (don’t be fooled by labels containing words like Natural, Whole, or even Organic – these words don’t necessarily mean healthy and you might be sabotaging your efforts to reach your goals!). Someone might say to you, “Oh you should be eating X amount of calories, and X grams of carbs, protein, and fat per day.” Well to someone who isn’t a registered dietitian, or, you know, experienced at memorizing food labels, this can be pretty overwhelming. But how much of these things should we be eating in a day? I personally believe every body functions differently, and there is no one set of magic numbers. On average, you want your diet to consist of approximately 50-60% carbohydrates, 15-20% Fat, and 15-20% Protein (The Dietary Guidelines for Americans). But like I said, these numbers are different for everyone. I know people who thrive on 30% fat, or even 75% carbs. It also depends on your goals. For general weight loss, I advise people to raise their protein, and lower their fat intake. There are a few reasons for this, but one major one is that protein helps to regulate your blood glucose. What the heck does that mean? To put simply, this means that the “carbs” your body gets from food is utilized in a slower, and more controlled manner – less spiking of your blood sugar levels. It’s like slow release energy – and you stay fuller, for longer! It is important to try and get protein and fat with all of your meals – just be mindful of your proportions! Carbs are your body’s main source of fuel, so enough with the low carb nonsense already! Just make smart carb decisions (whole grains, lots of veggies, etc). Ever wonder why your low-carb friend is such a biotch? Because the only source of fuel your brain uses is carbs! Nobody wants to be around a low-carb dieter (plus, when they go into ketosis, their breath smells naaasty. So now you’re practically PMSing and you have crazy bad breath. Sexy). Now I’m just going to warn you, there’s a bit of math involved here. Relax. Don’t freak out on me yet – it’s basic math, and I think the majority of us own a calculator (or at least have the app on our iPhone). So here’s the facts: 1 gram of carbohydrates = 4 calories 1 gram of fat = 9 calories 1 gram of protein = 4 calories 1 lb of fat = 3,500 calories So pull out your favorite packaged snack food, and let’s get cracking here: Let’s say you eat a 2/3 cup of pistachios every day. Nuts are good fats, right? And 2/3’s really isn’t that much (especially when left alone, and no one is looking you eat about 2 cups). No big deal right? Well let’s take a closer look, shall we? 2/3 cup of pistachios: 310 calories, 24 grams of fat, 13 grams of carbs, and 11 grams of protein To figure out what percentage of those calories comes from fat: 24 (grams of fat per 2/3 cup) x 9 (calories per gram of fat – see above) = 216 Now we take that 216 and divide by 310 (total number of calories from 2/3 cup of pistachios) = 0.7 Move the decimal, and we’ve figured out: 70% of the calories comes from fat. Yikes. Remember what I mentioned above? How you want your fat intake to be at about 15-20% (on the lower side if you’re trying to lose weight). This definitely is above that range… Let’s move on to protein: 11 (g of Protein) x 4 (cals per gram of protein) = 44 44 divided by 310 = 0.14 = 14% of the calories come from protein Not bad, but could be a bit higher. Carbohydrates: 13 (g of carbs in the nuts) x 4 (cals per gram of carbs) = 52 52 divided by 310 = 0.17 = 17% of the calories come from carbohydrates. Easy Peasy! But do you see why this would help someone make better food choices? The carbohydrates percentage is way too low, and the fat is way too high. Now try this simple formula on your favorite foods! Before we move totally away from math and word problems (bear with me!), I wanted to show you a bit more, looking at the dreaded cola. Let’s say you drink 2 colas a day (which you don’t really, right?). But let’s just say you do. Each cola is approximately 12 ounces (150 calories, 41 grams of carbs). If you drink those 2 colas every day: You’ve consumed 109,500 extra calories in one year And by replacing your cola with water you could, theoretically, lose 31 lbs of fat (109,500 ÷ 3500 (calories in 1 lb of fat)). I think I’ve made my point :)Teralee Trommeshauer lives in Castlegar, BC, and is a health, food, and fitness enthusiast currently working on her Holistic Nutrition and FItness Education certifications. This column originally appeared in her blog.last_img read more

first_imgThe country’s latest lotto millionaire almost didn’t get a chance to collect his huge cheque – after he forgot to take his winning ticket to lottery headquarters in Dublin today.Odhran Doherty, 23, became a millionaire on Saturday night last after dad Liam gave him what proved to be a winning lotto ticket.The young farmer, from The Glebe in Letterkenny, couldn’t believe his luck as he drove by chauffeur-driven limousine to Dublin today. But Odhran revealed how he was forced to tell the driver to turn back after he forgot to take his winning ticket with him.He said “I almost wasn’t collecting the money at all. We were up the road and heading towards Lifford when I realised I didn’t have the ticket.“I had to ask the driver to do a quick turnaround and head back to the house where I had the ticket hidden away.“Can you imagine if I had landed all the way to Dublin and they had asked for the ticket and I didn’t have it. How embarrassing would that have been?” And in a bizarre twist of luck, dad Liam has revealed how he is related to another lucky Donegal lotto winner who picked up his cheque just a few weeks ago.Pensioner Charlie Meehan, 84 was the toast of Donegal in February when he scooped €500,000 in the Euromillions draw.Bizarrely, both Liam and Odhran are working on a shed at Charlie’s house.Att he time Charlie said he had already won the lotto even before his numbers came up after he overcame cancer.Liam revealed “I am related to Charlie on my mother’s side and I was so delighted when I heard he had won the lotto. It couldn’t happen to a nicer man. Charlie is an absolute gentleman. “Little did I think that we would be collecting one million euro ourselves just a few weeks later.”Lotto millionaire Odhran forgets his winning ticket on way to collect cheque! was last modified: April 3rd, 2019 by StephenShare this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window)Tags:Chequedonegalletterkennylottowinnerlast_img read more

first_imgChris Samba is set to spend deadline day wondering whether Tottenham and QPR will table late bids for him.QPR boss Mark Hughes will be busy.The Daily Mail report that Turkish outfit Galatasary are also interested in the centre-back, who could be allowed to leave Blackburn if an offer in excess of £10m is made.Tottenham duo Steven Pienaar and Sebastien Bassong are among QPR’s many possible signings today – and The Guardian suggest both players are ‘desperate’ to move to Loftus Road.Fulham are expected to complete the signing of Stuttgart striker Pavel Pogrebnyak. The Mail say the club moved for him after an attempt to sign Borussia Dortmund’s Lucas Barrios stalled.West Brom have also shown an interest in Russia international Pogrebnyak but the 28-year-old is believed to be keen to move to LondonWigan’s Hugo Rodallega is on his way to QPR or Fulham, according to the Daily Star. But the Daily Mirror say Tottenham are ready to snatch Colombian forward.The Mirror also report Chelsea’s attempt to complete the £1m signing of 18-year-old striker Patrick Bamford from Nottingham Forest before the transfer window closes.Follow West London Sport on TwitterFind us on Facebooklast_img read more

first_imgQPR have been forced to make a number of changes for tonight’s game at Burton, where Conor Washington has again been asked to operate as a lone striker.Idrissa Sylla misses out through illness, Jordan Cousins has failed to recover from a hamstring problem in time, while Sebastian Polter, who has been nursing an ankle knock, is only fit enough for a place on the bench.Winger Yeni Ngbakoto is still out with a thigh problem. Sandro is among the R’s substitutes, as is former Burton man Nasser El Khayati.QPR: Smithies, Onuoha, Caulker, Hall, Bidwell, Wszolek, Borysiuk, Luongo, Henry, Chery, Washington.Subs: Ingram, Lynch, El Khayati, Polter, Shodipo, Sandro, Kakay.Burton: McLaughlin, Mousinho, McFadzean, Turner, Williamson, Atkins, Dyer, Ward, Naylor, Palmer, Irvine. Follow West London Sport on TwitterFind us on Facebooklast_img read more

first_imgNigerian surfer and instructor Godpower Pekipuma was born in Tarkwa Bay, the small beach community close to Lagos harbour, where man-made shipping inlets have helped to create naturalistic swells, perfect for surfing.pic.twitter.com/IDLxEDUib6— Godpower Pekipuma (@alloy_92938) February 3, 2016While surfing may not be the most popular sport in Nigeria, the young surfers Pekipuma teaches in the bay are discovering the natural thrill of the sport. He teaches 15 students, some as young as five, to tame the waves of Tarkwa, using borrowed, donated and makeshift boards.Young boys practice #surfing at the #tarkwa bay #lagos #nigeria #snapitoga #everydayafrica pic.twitter.com/8Qo2rtENjh— Snap It Oga (@snapitoga) July 8, 2016“It’s hard to practise more, because we don’t want to break our boards,” Pekipuma told BBC News. It’s the reason he wants to build a small local industry around the sport and the community, teaching residents to build boards. He is also planning on opening a surf shop where surfers can get advice and encouragement.Here’s What Beach Surfing On The Beaches Of Tarkwa Bay In Lagos Lokks Likehttps://t.co/P8dN8K8Pv9 pic.twitter.com/4DssuEjQ8D— Farabale (@FarabaleNow) April 28, 2016Together with Italian-born surf-tourist John Micheletti, Pekipuma also wants to spread the word to the international surfing community, both amateur and professional, inviting them to discover surfing, the Nigerian way.Tarkwa Bay local, John Michelleti, sent us a postcard update from Nigeria. Read it here – http://t.co/uUYDWF5aRd pic.twitter.com/v0qgAuDByB— Zigzag – SA Surf Mag (@Zigzagsurf) August 20, 2015Micheletti, who divides his time between the waves of Cape Town and Lagos, spreading the gospel of Tarkwa Bay to his fellow surfing journeymen, is determined to get the surfing world to experience the unique African surf culture. He told BBC News: “We want the world to see what we are doing, in our own humble way.”The sport is becoming popular enough that even the local film industry, known as Nollywood, is getting in on the action – recruiting Pekipuma, Micheletti and their students to make a surfing-themed movie titled The Ghost of Tarkwa Bay in 2017.Watch the BBC interview with Godpower Pekipuma and John Micheletti about surfing at Tarkwa Bay:Watch a CNN interview with Godpower Pekipuma about life as a surfer in Nigeria:Watch a short film about surfing Tarkwa Bay by surf tourist Armando Abraham, featuring John Micheletti and a great afro-funk soundtrack:Be inspired by a collection of Tarkwa surfing photos, courtesy of Godpower Pekipuma’s Facebook page:Source: BBC NewsSouthAfrica.info reporterWould you like to use this article in your publication or on your website? See: Using SouthAfrica.info materiallast_img read more